bluebird takes outcomes-based contracting off-the-shelf

There’s a market access crisis looming for gene therapies, and it could be the push manufacturers and payers need to build a system that can support broader, more standardized value-based contracts. 

With the approval of Zynteglo betibeglogene autotemcel in the U.S., bluebird bio Inc. (NASDAQ:BLUE) has taken an initial step, becoming the first company to launch a new gene therapy drug into the U.S. market with the offer of an “off-the-shelf” value-based contract for payers based on a clinical outcome that can be captured directly from claims data...